Department of Ultrasound, First Medical Center, Chinese PLA General Hospital, Beijing, China.
Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China.
Int J Surg. 2024 Aug 1;110(8):4867-4875. doi: 10.1097/JS9.0000000000001595.
BACKGROUND: Image-guided thermal ablation has been applied in patients with papillary thyroid microcarcinoma (PTMC) who refuse surgery or active surveillance. However, evidence to support ablation is limited by single-center designs and a lack of long-term data. The purpose of this study was to compare long-term outcomes between ablation and lobectomy for patients with solitary PTMC. MATERIALS AND METHODS: This multi-center retrospective study included 1021 consecutive patients with solitary PTMC who underwent ablation ( n =444) or lobectomy ( n =577) at the four university-affiliated hospitals. The primary outcomes were disease progression [lymph node metastasis (LNM), recurrent tumors, persistent tumors and distant metastasis] and disease-free survival (DFS). Secondary outcomes were complications, hospitalization, procedure time, estimated blood loss and cost. The two groups were compared using propensity score matching. RESULTS: After matching, no significant differences were observed in disease progression (4.7% vs. 3.4%, P =0.307), LNM (1.6% vs. 1.6%, P =1.000), recurrent tumors (2.9% vs. 1.8%, P =0.269), persistent tumors(0.2% vs. 0%, P =0.317) and DFS (95.5% vs. 97.1%, P =0.246) between the ablation and lobectomy groups during the median follow-up of 96.5 months. The ablation group had significantly lower complication rates (0.7% vs. 5.2%, P <0.001), shorter post-treatment hospitalization {median [interquartile range (IQR)], 0 vs. 4.0 [3.0] days, P <0.001}, shorter procedure time [8.5 (2.8) vs. 90.0 (43.8) min, P <0.001], reduced estimated blood loss [0 vs. 20.0 (10.0) ml, P <0.001], and lower cost [$1873.2 (254.0) vs. $2292.9 (797.8), P <0.001] than the lobectomy group. CONCLUSIONS: This study revealed comparable disease progression and survival outcomes between ablation and lobectomy for solitary PTMC. Imaged-guided thermal ablation could be effective and safe alternatives to lobectomy for properly selected patients with PTMC.
背景:影像引导下的热消融已应用于拒绝手术或主动监测的甲状腺微小乳头状癌(PTMC)患者。然而,由于单中心设计和缺乏长期数据,消融的证据有限。本研究旨在比较消融与甲状腺叶切除术治疗单发 PTMC 患者的长期疗效。
材料与方法:这项多中心回顾性研究纳入了在四所大学附属医院接受消融(n=444)或甲状腺叶切除术(n=577)治疗的 1021 例单发 PTMC 连续患者。主要结局为疾病进展(淋巴结转移[LNM]、复发性肿瘤、持续性肿瘤和远处转移)和无病生存(DFS)。次要结局为并发症、住院时间、手术时间、估计出血量和费用。两组采用倾向评分匹配进行比较。
结果:匹配后,消融组和甲状腺叶切除术组的疾病进展率(4.7% vs. 3.4%,P=0.307)、LNM(1.6% vs. 1.6%,P=1.000)、复发性肿瘤(2.9% vs. 1.8%,P=0.269)、持续性肿瘤(0.2% vs. 0%,P=0.317)和 DFS(95.5% vs. 97.1%,P=0.246)差异均无统计学意义。在中位随访 96.5 个月期间,消融组的并发症发生率(0.7% vs. 5.2%,P<0.001)、术后住院时间(中位数[四分位间距],0 vs. 4.0[3.0]天,P<0.001)、手术时间[8.5(2.8)vs. 90.0(43.8)分钟,P<0.001]、估计出血量[0 vs. 20.0(10.0)毫升,P<0.001]和费用[1873.2(254.0)vs. 2292.9(797.8)美元,P<0.001]均显著低于甲状腺叶切除术组。
结论:本研究表明,在单发 PTMC 中,消融与甲状腺叶切除术的疾病进展和生存结局相当。影像引导下的热消融可为选择合适的 PTMC 患者提供有效且安全的甲状腺叶切除术替代方案。
Front Endocrinol (Lausanne). 2025-7-24
Clin Endocrinol (Oxf). 2023-3
JAMA Otolaryngol Head Neck Surg. 2024-11-7
Front Endocrinol (Lausanne). 2023
Int J Hyperthermia. 2022